Weekly Digest - November 2026
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - November 2026
04 November 2026: Sino Biopharmaceutical enters strategic oncology partnership with Boehringer Ingelheim valued at up to US$7 billion
- Sino Biopharmaceutical entered its second oncology collaboration with Boehringer Ingelheim, covering six preclinical programmes across ADCs and TCEs, sourced from its subsidiaries LaNova Medicines (five) and Beijing Tide (one)
- Sino will lead development through completion of global Phase 1 trials, after which Boehringer Ingelheim can exercise options to secure exclusive global development and commercialization rights, with certain geographic exclusions for four programmes
- The agreement includes US$358 million in upfront and near-term payments, up to US$7 billion in potential milestone payments, and tiered royalties reaching double digits
- The deal highlights continued pharma interest in early-stage ADC and TCE assets, while giving Sino access to substantial milestone-based returns and providing Boehringer Ingelheim with options to expand its global oncology pipeline
